Sphingosine kinases (SphK 1&2) 
Introduction
Sphingosine kinases (SphK1&2) and their signal ling pathways are key regulators of cell survival, pro liferation and differentiation. Moreover, SphKs influ ence crucial functions of neurons such as the secretion of neurotransmitters or neurite shape. The SphK pro duct sphingosine1phosphate (S1P) may play the role of an intracellular second messenger or act through cell surface receptors. The extracellular presence of S1P is dependent on the translocation of SphK1 to the plasma membrane; SphK2 can also undergo intracel lular translocation, but the compartment and targets of S1P produced in such cases are different.
Accumulating evidence suggests the involvement of sphingosine kinases in a number of pathologi cal conditions. Ageing is the crucial risk factor for Alzheimer's and Parkinson's diseases (AD and PD, respectively). The enhanced neuronal vulnerability to oxidative stress in ageing may be a result of the dysregulation of membrane lipids including sphin golipids [15] . Disturbed S1P levels could also poten tially facilitate neurodegenerationlinked events such as ischaemic brain damage. S1P and especially its precursor, sphingosine, have already been found to possess some protective effects in the ischaemic heart model; it is tempting to speculate that it could be of interest in the brain ischaemia as well [36] . How ever, the results are highly unclear as S1P can be both cytoprotective [36] and sensitise the cells to oxidative stressinduced calcium dysregulation [5] ; its chang es in various organs seem to take different courses. The role of S1P in glutamatergic neurotransmission constitutes another important aspect of its potential influence of neuronal survival. The ischaemic damage is largely linked to a wave of uncontrolled neurotrans mitter secretion. S1P takes part in the regulation of neuronal excitability and learning and memory phe nomena [19] . It has been shown to trigger glutamate release and, importantly, to enhance depolarisation induced secretion of the neurotransmitter [16] .
It remains to be explained if conditions such as AD or PD can be affected by the agerelated distur bances of sphingosine signalling and if these chang es could create vulnerable background for the devel opment of such diseases. Some results indeed point to the possible role of SphKs in AD. Sphingolipid sig nalling influences amyloid beta (Aβ)induced inflam mation [18] . Moreover, Aβ inhibits SphK1 activity in SHSY5Y neuroblastoma [10] and selectively modu lates the expression of some S1P receptor subtypes in monocytes [18] . Disturbances in sphingolipid me tabolism are noted in AD starting from the earliest stages [20] with the levels of proapoptotic ceramide increased and activated catabolism of the usually prosurvival compound S1P. Importantly, changes observed correlate with cognitive decline. This phe nomenon may potentially constitute a crucial fac tor of neuronal death and the resulting dementia. The levels of ceramides (Cer16, Cer18, Cer20, and Cer24) are changed in AD brains [8] and serum d18:1C16:0 and d18:1C24:0 ceramides are associ ated with an increased AD risk [25] . SphK overex pression reduces the toxic effect of Aβ [10] . Inhib itors of selected enzymes involved in sphingolipid metabolism may be extremely promising tools in AD research. Moreover, ceramide stabilises betasecre tase and boosts Aβ levels while glycosphingolipid depletion inhibits APP maturation and transport [29, 34] . Thus, the ceramideS1P 'biostat' shows vast potential as a possible important point of ADrelated pathology.
Amyloid β and its precursor protein (APP) have long been viewed among the central elements of neuronal survival and death. However, more recent research has suggested that αsynuclein (ASN) may also be a factor of AD pathology. ASN is a small pep tide of up to 140 amino acids; β and γsynucleins have also been identified. All synucleins are enriched in the central nervous system, particularly in the structures affected by AD: the neocortex, hippocampus and sub stantia nigra.
Despite classically being viewed as an intracellu lar protein, ASN has recently been found to undergo secretion [11] and uptake to the surrounding cells [22] . ASN is found in intracellular Lewy bodies pres ent in Parkinson's disease and in ca. 60% of Alzhei mer's disease (AD) cases. Moreover, a fragment of αsynuclein dubbed nonAβ component of AD amy loid (NAC) is found in Aβ plaques in Alzheimer's and other diseases [35] . The immunoreactivity of ASN it self was also found in mature core amyloid plaques [3] . αsynuclein enhances amyloid β secretion from cells in culture twofold [21] . ASN also potentiates Aβ toxicity; this leads to mitochondrial damage and programmed cell death in a mode probably depen dent on the Aβ load [21] . ASN could facilitate Aβ aggregation [24] , though ASNdeficient models can also show accelerated Aβ aggregation [17] . The ASN level is increased in AD [3] . Finally, membranebound ASN physically interacts with amyloid β [24] , though its mechanism and exact significance are highly unclear.
The currently available data suggest potential links between sphingolipid signalling and αsynucle in. Moreover, ASN may be engaged in Alzheimer's disease and modify the metabolism and fate of amy loid β precursor protein. The aim of our work was to investigate the possible link between sphingosine kinase signalling, ASN and the production and secre tion of APP.
Material and methods
Dulbecco's modified Eagle's medium (DMEM)/ F12 and other cell media as well as inorganic reagents were from Wako. Alltrans retinoic acid was from SigmaAldrich. AntiAPP (clone# 22C11) antibody was purchased from Millipore. SphK inhibitors were from Calbiochem; S1P from Biomol.
The human SHSY5Y neuroblastoma cell line is known to be able to both proliferate and differen tiate in culture and is able to express a number of neuronal features including beta dopamine hydro xy lase activity and cholinergic and glutamatergic phenotypes. Lowpassage (< 16), stably transfected wtASNexpressing SHSY5Y cells were used for quan titative studies of S1P and SKI influence. As αsynu clein undergoes proteolytic degradation in certain cell states and alltrans retinoic acid (ATRA)induced cell differentiation inhibits this phenomenon [30] , we treated the cultures for five days with 10 µM ATRA. ATRA induced morphological changes towards a more arborised phenotype as shown in Fig. 1A . The sur vival of the differentiated cell line was found to be unaffected by the concentrations of S1P or SKI used, which differs somewhat from the situation in nondif ferentiated cells.
As the endogenous ASN levels were still very low (data not shown), a stably transfected cell line was prepared for use in the ASN quantification experi ments. Standard molecular biology methods were employed. A fulllength human ASN sequence was cloned from total RNA using proofreading RTPCR 
The SphK product, sphingosine1phosphate (S1P), and the potent, selective sphingosine kinase inhibitor (SKI) were both used at concentrations of 0.1, 1.0 and 5.0 µM, respectively.
For the measurements of intracellular and secret ed APP lowpassage, wtASNexpressing cells were seeded at 0.8 × 10 5 /well onto sixwell dishes and cultured overnight in DMEM/F12 with 10% foetal calf serum, penicillin + streptomycin and 5 µg/ml blas ticidin to achieve ~10% confluence. 10 µM ATRA was then added fresh every day for 120 h. After differentiation the cells were switched to serum free DMEM/F12 medium and APP was collected for three days. The medium was centrifuged and dena tured in a Laemmli sample buffer. The cells were washed twice with phosphatebuffered saline (PBS), scraped in 0.9 ml of PBS, centrifuged and lysed for 30 minutes at 4°C in 0.25 ml of 50 mM TrisHCl pH 7.5 containing 150 mM NaCl, 0.5% Nonidet P40. 5 mM EDTA and Complete™ protease inhibitors. The lysates were cleared by centrifugation and dena tured. After measurements of protein contents the denatured medium and cell extracts were resolved using sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDSPAGE) together with BioRad Precision Plus Protein WesternC standards. After transfer to nitrocellulose membranes, the nonspe cific binding was blocked with 5% skim milk for two hours at room temperature and westernblots were performed using 1 : 100 "22C11" antiAPP antibody in Tween20containing Trisbuffered saline (TTBS) and after washes with 1 : 10 000 antimouse horserad ish peroxidase (HRP)linked secondary IgG together with 1 : 10 000 StreptactinHRP conjugate in 0.5% milk/TTBS for 1 h. The chemiluminescent (ECL) sig nal was measured with a LAS1000 apparatus (Fuji) and quantitated using ImageJ software. The statisti cal significance of the obtained results was assessed using Student's t-test.
Results
The endogenous level of APP was detectable in the SHSY5Y cell line; it was possible to quantitate the secretion of APP protein after three days of incu bation in control conditions. The expression of wtASN (Fig. 1A) caused an increase of the cell extract APP signal in nondifferentiated SHSY5Y cells to 313% of the values observed in nontransfected cells (Fig. 1B) . Moreover, preliminary results suggest that a similar change could occur also in secreted APP (data not shown).
To characterise the molecular mechanisms of APP modulation we used the sphingosine kinase product S1P and an inhibitor of both SphK isoforms termed SKI. The 72 h treatment with 5 µM S1P caused a reduction of APP signal in the extracts of differen tiated SHSY5Y cells to 51% of the control (p < 0.05; Fig. 2A ) with an insignificant increase in secretion (Fig. 2B) . The effect of S1P on the APP level in the extract was nearly identical (46% of the appropriate control, not shown in the figures) when nonASN transfected cells were used.
5 µM SKI administered to the differentiated ASNtransfected cells in the same conditions caused a significant increase of the cellular APP level (5 µM: 121%; p < 0.01; Fig. 3A) . Correspondingly, the APP signal in the medium was reduced (54% of control; p < 0.02; Fig. 3B ) while lower concentrations did not induce significant changes (APP secretion at 98% of the control level for 0.1 µM SKI and 80% for 1 µM SKI).
Discussion
The dysregulation of membrane lipids takes place in ageing, which is the most important risk factor for neurodegenerative disorders [15] . Disturbed sphingo lipid metabolism could also directly affect agerelated neurodegenerative diseases such as AD, PD or cere bral ischaemia. This could take place e.g. through the numerous functions of S1P in neuron generation, sur vival, neurite retraction/extension, neurotransmit ter release [1, 28] , and its ambiguous role in oxidative stresslinked events (glutathione depletion leading to H 2 O 2 sensitivity in PC12 cells vs. heart protec tion against ischaemia/reperfusion injury) [5, 36] . In the current work, we assessed the role of S1P in the ASNdependent expression and secretion of APP in SHSY5Y neuroblastoma cells.
ASN is enriched in the central nervous system (CNS) structures particularly affected by AD. Our pre vious work suggested a link between ASN and Aβ. ASN was able to increase the Aβ secretion and tox icity to a point where it caused cell death [21] . Other results suggest that ASN could influence Aβ aggre gation, though the results are far from clear [17, 24] . The two proteins can also physically bind each other [24] . Our current work shows that the precursor pro tein for Aβ is also influenced by ASN. The expression of wt αsynuclein has led to a significant increase of endogenous APP in SHSY5Y cells. This suggests that APP level and/or secretion might be positively depen dent on the intracellular level of ASN. In the study by Kazmierczak et al. [21] , ASN was added externally and it was possible that its action could have been mediated by cell surface structures or even occurred outside the cell [21] . Our current results suggest that B the phenomenon should be linked to the metabo lism of Aβ precursor protein rather than occurring (only) at the level of APP cleavage/Aβ. Sphingosine kinases undergo precise regula tion through posttranslational modifications [6] , differential subcellular translocation [6, 14] , binding partners [9, 12] , and have partially different targets [14, 27, 28] . Each may be an important factor of AD albeit in different ways. Sphingolipid signalling may influence Aβ production [29, 32, 34] and siRNA/inhi bition of SphK1/SphK2 reduces βcleavage of APP leading to lower the secretion of Aβ and sAPPβ [33] . SphKs and sphingolipids may also modulate Aβ tox icity [7, 10] and the inflammation it causes [18] as well as the resulting brain tissue damage [2] . In turn, Aβ inhibits S1P production [10] and modulates S1P receptors [18] . A correlation of sphingolipid distur bances with cognitive decline was observed in AD [20] and the protective influence of SphKs in Aβ tox icity has been reported [10] .
We found that the SphK product S1P lowered the cellular level of APP. The influence of S1P on the secretion of APP showed a tendency towards acti vation, though the results were insignificant. SKI caused a dosedependent decrease of medium APP levels, reaching a statistical significance at 5 µM. 
B
The cellular level of APP was significantly elevated. Based on these results it is reasonable to suggest that in fact the influence of S1P on APP might be prosecretory. Such a conclusion would be consis tent with the ubiquitous [4, 16, 26] and physiological ly relevant [19] prosecretory influence of S1P [28] .
Results suggesting the influence of the ceramide/ sphingolipid signalling on the processing of APP have been published [23] . It is thus reasonable to expect that its actual influence on APP secretion will follow the general trend despite the fact that the various examples seem to employ an array of somewhat dif ferent mechanisms. S1P has been found to directly bind (probably the transmembrane and intracellular domains) and modulate the activity of BACE1, the ratelimiting enzyme for Aβ production [33] . The ten dency towards higher APP levels in the medium and the reduction of its cellular content in the SHSY5Y line strongly suggest that the secretion of whole APP probably masks the reduction that would stem from the mentioned increased cleavage. This is analogous to some degree to the situation in hamster ovary cells where the secretion of Aβ 142 follows the profile of APP secretion [31] . In these cells the influence of sphingolipids seemed to be different from its role in neuroblastoma (and probably the brain). Sphingoli pid deficiency enhanced the secretion of the products of nonamyloidogenic αcleavage of overexpressed human APP75 (with amyloidogenic cleavage prod ucts unchanged or reduced), an effect mediated by the MAPK/ERK pathway and rescued by sphingosine treatment [31] . This suggests that the various steps of the sphingolipid pathway may influence different aspects of APP/Aβ metabolism in opposite ways; moreover, sphingolipid action may differ significant ly between the CNS and the periphery. The chronic nature of AD and the extremely elongated period of changes preceding its clinical manifestation fur ther suggest that even very subtle changes in APP metabolism could have tremendous effects on the state of CNS either taken alone or in combination with simultaneously occurring pathological changes. Although both ASN and APP undergo regulation by the SphK pathway, APP does not appear to fol low the S1P metabolisminduced changes of ASN. We observed rather unexpected results regarding the influence of the S1P pathway on ASN secretion. Both S1P and SKI elevated the ASN signal in the medi um without affecting the cellular level significantly (unpublished own results). Somewhat analogous re sults were obtained by Takasugi et al. [33] in a study on APP cleavage suggesting differential roles of cellu lar vs. exogenous S1P in these processes. It is possi ble that the influence of sphingolipid metabolism on ASN (which is limited to its secretion) does not mod ify the production of APP, which could be dependent mainly on the intracellular ASN level. Another expla nation is that APP might undergo an additional level of SphKrelated regulation working between ASN and APP production, as suggested by the different types of effects of SKI and S1P on APP vs. ASN.
Our results suggest a potentially important link between ASN and APP/Aβ. The interactions between these proteins may open new views on the devastat ing pathologies and possibly lead to a more compre hensive understanding of these processes.
